Detalhe da pesquisa
1.
Homologous and Heterologous Covid-19 Booster Vaccinations.
N Engl J Med
; 386(11): 1046-1057, 2022 03 17.
Artigo
Inglês
| MEDLINE | ID: mdl-35081293
2.
A Phase 2 Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A(H7N9) Inactivated Influenza Virus Vaccines Administered with and without AS03 Adjuvant in Healthy US Adults.
Clin Infect Dis
; 2024 Mar 27.
Artigo
Inglês
| MEDLINE | ID: mdl-38537255
3.
A Multicenter, Controlled Human Infection Study of Influenza A(H1N1)pdm09 in Healthy Adults.
J Infect Dis
; 228(3): 287-298, 2023 08 11.
Artigo
Inglês
| MEDLINE | ID: mdl-36702771
4.
Immunogenicity of a 2-Dose Regimen of Moderna mRNA Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical Trial.
J Infect Dis
; 228(12): 1662-1666, 2023 12 20.
Artigo
Inglês
| MEDLINE | ID: mdl-37561027
5.
Immunogenicity of the BA.1 and BA.4/BA.5 Severe Acute Respiratory Syndrome Coronavirus 2 Bivalent Boosts: Preliminary Results From the COVAIL Randomized Clinical Trial.
Clin Infect Dis
; 77(4): 560-564, 2023 08 22.
Artigo
Inglês
| MEDLINE | ID: mdl-37036397
6.
An mRNA Vaccine against SARS-CoV-2 - Preliminary Report.
N Engl J Med
; 383(20): 1920-1931, 2020 11 12.
Artigo
Inglês
| MEDLINE | ID: mdl-32663912
7.
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults.
N Engl J Med
; 383(25): 2427-2438, 2020 12 17.
Artigo
Inglês
| MEDLINE | ID: mdl-32991794
8.
SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination.
N Engl J Med
; 386(11): 1088-1091, 2022 03 17.
Artigo
Inglês
| MEDLINE | ID: mdl-35081298
9.
Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19.
N Engl J Med
; 384(23): 2259-2261, 2021 06 10.
Artigo
Inglês
| MEDLINE | ID: mdl-33822494
10.
Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination.
N Engl J Med
; 384(1): 80-82, 2021 01 07.
Artigo
Inglês
| MEDLINE | ID: mdl-33270381
11.
Recombinant Porcine Reproductive and Respiratory Syndrome Virus Expressing Membrane-Bound Interleukin-15 as an Immunomodulatory Adjuvant Enhances NK and γδ T Cell Responses and Confers Heterologous Protection.
J Virol
; 92(13)2018 07 01.
Artigo
Inglês
| MEDLINE | ID: mdl-29643245
12.
A Universal Influenza Vaccine: The Strategic Plan for the National Institute of Allergy and Infectious Diseases.
J Infect Dis
; 218(3): 347-354, 2018 07 02.
Artigo
Inglês
| MEDLINE | ID: mdl-29506129
13.
A SARS-CoV-2 mRNA Vaccine - Preliminary Report. Reply.
N Engl J Med
; 383(12): 1191-1192, 2020 09 17.
Artigo
Inglês
| MEDLINE | ID: mdl-32813942
14.
Alternating electric fields (TTFields) in combination with paclitaxel are therapeutically effective against ovarian cancer cells in vitro and in vivo.
Int J Cancer
; 139(12): 2850-2858, 2016 Dec 15.
Artigo
Inglês
| MEDLINE | ID: mdl-27561100
15.
Ovarian tumor-initiating cells display a flexible metabolism.
Exp Cell Res
; 328(1): 44-57, 2014 Oct 15.
Artigo
Inglês
| MEDLINE | ID: mdl-25172556
16.
Membrane-bound IL-12 and IL-23 serve as potent mucosal adjuvants when co-presented on whole inactivated influenza vaccines.
Virol J
; 11: 78, 2014 May 03.
Artigo
Inglês
| MEDLINE | ID: mdl-24884849
17.
Metabolic changes during ovarian cancer progression as targets for sphingosine treatment.
Exp Cell Res
; 319(10): 1431-42, 2013 Jun 10.
Artigo
Inglês
| MEDLINE | ID: mdl-23518387
18.
Biomechanical profile of cancer stem-like/tumor-initiating cells derived from a progressive ovarian cancer model.
Nanomedicine
; 10(5): 1013-9, 2014 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-24407147
19.
Immunogenicity and safety of varying dosages of a fifth-wave influenza A/H7N9 inactivated vaccine given with and without AS03 adjuvant in healthy adults.
Vaccine
; 42(2): 295-309, 2024 01 12.
Artigo
Inglês
| MEDLINE | ID: mdl-38105137
20.
Obesity modulates the cellular and molecular microenvironment in the peritoneal cavity: implication for ovarian cancer risk.
Front Immunol
; 14: 1323399, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-38264656